ReviewMediators of inflammation2022
Biological Activities Underlying the Therapeutic Effect of Quercetin on Inflammatory Bowel Disease.
Review in Mediators of inflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- A Systematic Review: Quercetin-Secondary Metabolite of the Flavonol Class, with Multiple Health Benefits and Low Bioavailability.International journal of molecular sciences · 2024Pooled it
- Quercetin Alleviates Neuroinflammation in Chronic Insomnia by Modulating the RAGE/NF-κB Signaling Pathway: Insights from Network Pharmacology and In Vitro Validation.Biomedicines · 2026Article
- The methanolic extract of Byrsonima intermedia mitigates colonic injury in experimental colitis through redox restoration, cytokine modulation, and tissue repair.Inflammopharmacology · 2026Article
- Himalayan medicinal plants for gastrointestinal disorders: ethnopharmacology and mechanistic insights.Inflammopharmacology · 2026Review
- Electrosprayed Alginate-Fmoc Amino Acid Microcapsules for Quercetin Loading and Release.ACS omega · 2026Article
- Food-grade TiOJournal of nanobiotechnology · 2026Article
- Anti-Inflammatory Effects of Flavonoids in an LPS-Induced In Vitro Model of Canine Chronic Enteropathy.Animals : an open access journal from MDPI · 2026Article
- The Molecular Landscape of Inflammation in Inflammatory Bowel Disease (IBD): Targets for Precision Medicine.Biomedicines · 2025Review
- Exploring the molecular mechanism of apigenin in treating bronchiectasis based on network pharmacology and molecular docking.Scientific reports · 2025Article
- Article
- Flavonol Technology: From the Compounds' Chemistry to Clinical Research.Molecules (Basel, Switzerland) · 2025Review
- Quercetin Can Alleviate ETECK88-Induced Oxidative Stress in Weaned Piglets by Inhibiting Quorum-Sensing Signal Molecule Autoinducer-2 Production in the Cecum.Antioxidants (Basel, Switzerland) · 2025Article
- Development and Validation of a LC-QTOF-MS/MS Method to Assess the Phenolic Profile of Pulse Flours.Molecules (Basel, Switzerland) · 2025Article
- Anti-Inflammatory Actions of Plant-Derived Compounds and Prevention of Chronic Diseases: From Molecular Mechanisms to Applications.International journal of molecular sciences · 2025Review
- The Effects of Quercetin on Vascular Endothelium, Inflammation, Cardiovascular Disease and Lipid Metabolism-A Review.Nutrients · 2025Review
- Xiahuo Pingwei San attenuated intestinal inflammation in dextran sulfate sodium-induced ulcerative colitis mice through inhibiting the receptor for advanced glycation end-products signaling pathway.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Insights into rutin and quercetin biotransformations in ruminants revealed by molecular networking.Journal of animal science · 2025Article
- Research progress on the use of polyphenols in the treatment of Crohn's disease.Frontiers in pharmacology · 2025Review
- Review
- An anti-senescence hydrogel with pH-responsive drug release for mitigating intervertebral disc degeneration and low back pain.Bioactive materials · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic autoimmune disorder stemming from unrestrained immune activation and subsequent destruction of colon tissue. Genetic susceptibility, microbiota remodeling, and environmental cues are involved in IBD pathogenesis. Up to now, there are limited treatment options for IBD, so better therapies for IBD are eagerly needed. The therapeutic effects of naturally occurring compounds have been extensively investigated, among which quercetin becomes an attractive candidate owing to its unique biochemical properties. To facilitate the clinical translation of quercetin, we aimed to get a comprehensive understanding of the cellular and molecular mechanisms underlying the anti-IBD role of quercetin. We summarized that quercetin exerts the anti-IBD effect through consolidating the intestinal mucosal barrier, enhancing the diversity of colonic microbiota, restoring local immune homeostasis, and restraining the oxidative stress response. We also delineated the effect of quercetin on gut microbiome and discussed the potential side effects of quercetin administration. Besides, quercetin could serve as a prodrug, and the bioavailability of quercetin is improved through chemical modifications or the utilization of effective drug delivery systems. Altogether, these lines of evidence hint the feasibility of quercetin as a candidate compound for IBD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.